| Literature DB >> 25685908 |
Binbin Xia1, Lu Bai2, Xiaorong Li3, Jie Xiong4, Pinxiang Xu5, Ming Xue6.
Abstract
Although zebrafish has become a significant animal model for drug discovery and screening, drug metabolism in zebrafish remains largely unknown. Asiatic acid (AA) and madecassic acid (MA), two natural pentacyclic triterpenoids mainly obtained from Centella asiatica (L.) Urban, have been found to possess many pharmacological effects. This study is to probe the metabolic capability of zebrafish via investigation of the drug metabolism of AA and MA in zebrafish, using a sensitive LC/IT-MSn method. In addition, the main fragmentation pathways of AA and MA were reported for the first time. Nineteen metabolites of AA and MA were firstly identified after zebrafish was exposed to the drug, which all were the phase I metabolites and mainly formed from hydroxylation, dehydrogenation, hydroxylation and dehydrogenation, dihydroxylation and dehydrogenation, and dehydroxylation reaction. The results indicated that zebrafish possessed strong metabolic capacity, and the metabolites of AA and MA were formed via similar metabolic pathways and well matched with the known metabolic rules in vivo and in vitro, which supports the widely use of this system in drug metabolism research. This investigation would also contribute to the novel information on the structural elucidation, in vivo metabolites and metabolic mechanism of pentacyclic triterpenoids.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25685908 PMCID: PMC6272356 DOI: 10.3390/molecules20023001
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Chromatographic retention times, mass spectrometric data of AA and MA.
| Metabolites | Precursor Ion ([M−H]−) | Retention Time (min) | Data-Dependent MSn Data (Collision Energy: 36%; Relative Abundance: % Base Peak) |
|---|---|---|---|
| AA | 487 | 37.57 | MS2[487]:487(35), 473(4), 443(3), 441(7), 423(4), 421(19), |
| MS3[487→441]:421(20), | |||
| MS3[487→409]:391(50), | |||
| MS3[487→391]: | |||
| MS3[487→379]:379(8), 377(43), | |||
| MS4[487→441→409]:391(28), | |||
| MS4[487→409→379]:377(16), | |||
| MA | 503 | 30.51 | MS2[503]:503(96), 485(43), 465(12), 453(41), 435(33), 419(42), |
| MS3[503→485]:485(2), 465(14), 453(59), | |||
| MS3[503→407]:407(3), 405(20), | |||
| MS3[503→389]:389(85), 387(18), | |||
| MS4[503→407→389]:389(2), | |||
| MS4[503→485→453]:453(60), 451(35), | |||
| MS4[503→485→435]:435(60), | |||
| MS5[503→485→453→435]:435, 417, 407, 391 | |||
| MS3[503→391]: | |||
| MS4[503→391→375]: | |||
| MS4[503→391→363]: |
Figure 1Main fragment ions and fragmentation pathways of the [M−H]− ions of AA and MA (AA: R = H, MA: R = OH).
Figure 2LC-MS/MS chromatograms of AA at m/z 487 (A) and its metabolites with zebrafish exposure at m/z 487 (B), m/z 485(C), m/z 503 (D), m/z 501(E), m/z 517(F).
Figure 3The MSn (n = 2–3) spectra of the metabolites (A0–A10) of asiatic acid after zebrafish exposure: A0 (m/z 487); A1 (m/z 487, m/z 487→409), A2, A3 and A4 (m/z 485, m/z 485→407 ); A5 (m/z 503, m/z 503→485); A6 (m/z 503, m/z 503→457); A7 (m/z 503, m/z 503→407); A8 and A9 (m/z 501, m/z 501→455); and A10 (m/z 517, m/z 501→471).
Chromatographic retention times, mass spectrometric data of potential metabolites of AA (A1–A10) and MA (M1–M9).
| Metabolites | Precursor Ion ([M−H]−) | Retention Time (min) | Data-Dependent MSn Data (Relative Abundance: % Base Peak) |
|---|---|---|---|
| A1 | 487 | 28.01 | MS2[487]: 487, 473, 443, 441, 421, |
| MS3[487→409]: 407, 391, 389, | |||
| A2 | 485 | 22.09 | MS2[485]: 485, 455, 439, 419, 417, |
| MS3[485→455]: 455, 439, 425, | |||
| MS3[485→439]: 439, 419, 417, | |||
| MS3[485→407]: | |||
| MS4[485→407→389]: | |||
| A3 | 485 | 27.39 | MS2[485]: 485, 455, 439, 419, 417, |
| MS3[485→455]: | |||
| MS3[485→439]: 439, | |||
| MS3[485→407]: 389 | |||
| MS4[485→407→389]: 389, | |||
| A4 | 485 | 35.90 | MS2[485]: 485, 471, 455, 439, 419, 417, |
| MS3[485→455]: | |||
| MS3[485→439]: | |||
| MS3[485→407]: | |||
| MS4[485→407→389]: | |||
| A5 | 503 | 22.22 | MS2[503]: 503, |
| MS3[503→485]: 467, 439, 419, 417, | |||
| MS4[503→485→407]: 391, 389, | |||
| A6 | 503 | 24.15 | MS2[503]: 503, 487, 467, 457, |
| MS3[503→457]: | |||
| MS4[503→457→407]: | |||
| A7 | 503 | 30.42 | MS2[503]: |
| MS3[503→453]: 453, 435, | |||
| MS3[503→407]: 407, | |||
| A8 | 501 | 22.94 | MS2[501]: 501, 457, |
| MS3[501→457]: 457, 455, 439, 437, | |||
| MS3[501→455]: 455,439, 437, 425, 423, | |||
| MS3[501→423]: | |||
| MS3[501→379]: | |||
| MS4[501→455→407]: | |||
| A9 | 501 | 26.01 | MS2[501]: |
| MS3[501→455]: 455,439, 437, 425, 423, 409, | |||
| A10 | 517 | 20.24 | MS2[517]: 517, 499, 487, 473, |
| MS3[517→471]: | |||
| MS4[517→471→441]: | |||
| MS4[517→471→455]: | |||
| M1 | 501 | 18.50 | MS2[501]: 501, |
| MS3[501→483]: 435, | |||
| MS3[501→435]: | |||
| MS3[501→407]: | |||
| MS3[501→389]: | |||
| M2 | 501 | 24.49 | MS2[501]: 501, 483, 471, |
| MS3[501→455]: | |||
| MS3[501→407]: 407, | |||
| M3 | 501 | 28.86 | MS2[501]: 501, |
| MS3[501→455]: 483, 453, 437, 435, 417, 407, 405, 389, 387, | |||
| M4 | 501 | 36.40 | MS2[501]: 501, 483, 463, 437, 435, 433, 419, 407,405, |
| MS3[501→389]: 389, | |||
| M5 | 487 | 32.51 | MS2[487]: 487, 469, 457,441, |
| MS3[487→423]: | |||
| M6 | 487 | 37.93 | MS2[487]: 487, 457,441, 419, |
| MS3[487→409]: | |||
| M7 | 517 | 17.12 | MS2[517]: 517, 501, |
| MS3[517→471]: 453, 435, 423, | |||
| MS3[517→453]: 435, | |||
| MS3[517→423]: 407, | |||
| MS4[517→471→453]: 453, 435, 425, 423, 407, | |||
| MS4[517→471→423]: 423, | |||
| MS4[517→471→405]: | |||
| M8 | 519 | 13.47 | MS2[519]: 519, |
| MS3[519→501]: 483, | |||
| MS3[519→483]: 483, 471, 435, 417, 407, 405, 389, 371, 363, 361,
| |||
| MS4[519→501→483]: 465, | |||
| M9 | 533 | 14.74 | MS2[533]: 533, 489, |
| MS3[533→489]: 489, 471, 441, | |||
| MS3[533→487]: | |||
| MS4[533→489→471]:423, 405, 395, 381, | |||
| MS4[533→487→469]: 469, 454, |
Presupposed metabolic types and the m/z changes for potential metabolites of AA and MA.
| Description | Molecular Formula Change | |
|---|---|---|
| Decarboxylation | −CO2 | −44 |
| Hydroxymethylene loss | −CH2O | −30 |
| Demethylation | −CH2 | −14 |
| Hydroxylation + dehydration | −2H | −2 |
| Dehydrogenation | −2H | −2 |
| Demethylation + hydroxylation | −CH2, +O | +2 |
| Methylene to ketone | −2H+O | +14 |
| Hydroxylation + dehydrogenation | −2H+O | +14 |
| Methylation | +CH2 | +14 |
| Hydroxylation | +O | +16 |
| Methyl to carboxylation | −2H+2O | +30 |
| Hydroxylation and methylation | +CH2O | +30 |
| Dihydroxylation+ dehydrogenation | +2O, −2H | +30 |
| Dihydroxylation | +2O | +32 |
| Tri-hydroxylation + dehydrogenation | +3O, −2H | +46 |
| Tri-hydroxylation | +3O | +48 |
| Glycine conjugation | +C2H3NO | +57 |
| Sulfation | +SO3 | +80 |
| Hydroxylation and sulfation | +SO4 | +96 |
| Cysteine conjugation | +C3H5NOS | +103 |
| Taurine conjugation | +C2H5NO2S | +107 |
| S,N-Acetylcysteine onjugation | +C5H7NO2S | +145 |
| Glucosidation | +C6H10O5 | +162 |
| Glucuronide conjugation | +C6H8O6 | +176 |
| Hydroxylation + glucuronide | +C6H8O7 | +192 |
| Glutathione conjugation | +C10H15N3O6S | +305 |
| Glutathione conjugation | +C10H17N3O6S | +307 |
Figure 4LC-MS/MS chromatograms of MA and its metabolites at m/z 503 (A), m/z 501 (B), m/z 487(C), m/z 517 (D), m/z 519 (E), m/z 533(F) with zebrafish exposure.
Figure 5The MSn (n = 2–3) spectra of the metabolites (M0–M10) of MA after zebrafish exposure: M0 (m/z 503); M1, M3 (m/z 501, m/z 501→483), M2 (m/z 501, m/z 501→455), M4 (m/z 501, m/z 501→389); M5 (m/z 487, m/z 487→423); M6 (m/z 487, m/z 487→409); M7 (m/z 517, m/z 517→471); M8 (m/z 519, m/z 519→483); and M9 (m/z 533, m/z 533→487).
Figure 6The main putative metabolites and proposed metabolic pathways of AA and MA in zebrafish.